Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced upcoming oral (platform) and poster presentations at the 21st Annual WORLD Symposium ™, which will be held February 3-7, 2025, in San Diego, California. The oral presentation includes clinical results related to its Hunter syndrome (MPS II) investigational therapeutic, tividenofusp alfa (DNL310). Tividenofusp alfa is enabled by the Denali TransportVehicle™ platform, which is designed to effectively deliver enzyme, oligonucleotide, or antibody therapeutics to all tissues in the body, including the brain by crossing the blood-brain barrier.
The presentation schedule at WORLD Symposium ™ 2025 is as follows:
Title: Interim Analysis of Efficacy and Safety of Weekly Intravenous Tividenofusp Alfa in Mucopolysaccharidosis Type II (MPS II) – Platform Presentation
Session: Clinical Applications Platform Presentations
Date: Thursday, February 6, 2025
Session Time: 8:30 AM Pacific Time
Title: Unmet Needs in the Treatment and Care of Somatic Manifestations in People with Mucopolysaccharidosis Type II (Hunter Syndrome): A Targeted Literature Review – Poster #44
Session: Translational Research – Poster Session II
Date: Thursday, February 6, 2025
Session Time: 3:30 – 5:30 PM Pacific Time
Title: Age-Dependent Reference Intervals for Cerebrospinal Fluid (CSF) and Urine Heparan Sulfate (HS) and Dermatan Sulfate (DS) and CSF Gangliosides – Poster #132
Session: Clinical Applications – Poster Session III
Date: Thursday, February 6, 2025
Session Time: 3:30 – 5:30 PM Pacific Time
Denali is also sponsoring the following satellite symposium event at WORLD Symposium ™ 2025:
Title: Voices in Unison – Insights into the Unmet Needs in MPS II from Patient Community and Physician Perspectives (Chair: Barbara K. Burton, M.D.; Speakers: Joseph Muenzer, M.D., Ph.D. and Kristin McKay, President and Executive Director of Project Alive)
Date: Wednesday, February 5, 2025
Time: 6:45 – 7:45 AM Pacific Time
About Denali Therapeutics
Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the blood-brain barrier and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco. For additional information, please visit www.denalitherapeutics.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements by Denali Therapeutics Inc. ('Denali' or the 'Company') regarding Denali's planned presentations and events at the 2025 WORLD Symposium ™ and expectations related to Denali's TransportVehicle™ (TV) platform. Actual results are subject to risks and uncertainties and may differ materially from those indicated by these forward-looking statements as a result of these risks and uncertainties, including but not limited to: Denali's dependence on successful development of its BBB platform technology and TV-enabled product candidates; Denali's ability to initiate and enroll patients in its current and future clinical trials; Denali's ability to conduct or complete clinical trials on expected timelines; Denali's reliance on third parties for the manufacture and supply of its product candidates for clinical trials; the potential for clinical trial results to differ from preclinical, early clinical, preliminary or expected results; the risk of significant adverse events, toxicities, or other undesirable side effects; the risk that results from early clinical biomarker studies will not translate to clinical benefit in late clinical studies; the risk that product candidates may not receive regulatory approval necessary to be commercialized; developments relating to Denali's competitors and its industry, including competing product candidates and therapies; Denali's ability to obtain, maintain, or protect intellectual property rights; and other risks and uncertainties. In light of these risks, uncertainties, and assumptions, the forward-looking statements in this press release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Denali's product candidates are investigational, and their safety and efficacy profiles have not yet been established. No Denali product candidates have been approved by any health authority for any use. Information regarding additional risks and uncertainties may be found in Denali's Annual and Quarterly Reports filed on Forms 10-K and 10-Q filed with the Securities and Exchange Commission (SEC) on February 28, 2024, and November 6, 2024, respectively, and Denali's future reports to be filed with the SEC. Denali does not undertake any obligation to update or revise any forward-looking statements, to conform these statements to actual results or to make changes in Denali's expectations, except as required by law.
Laura Hansen, Ph.D.
(650) 452-2747
Media Contact
Rich Allan
FGS Global
(503) 851-0807
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension
NORCROSS, Ga., June 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will host a virtual key opinion leader (KOL) event on Monday, June 16, 2025 at 12:00 PM ET. To register, click here. The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include: Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell Biology and Physiology, & Director of Terance Kahn Liver Research Program, Indiana University School of Medicine; and Naim Alkhouri, MD, FAASLD, DABOM, Chief Academic Officer, Summit Clinical Research, & Director of the Steatotic Liver Program, North Shore Gastroenterology, Cleveland, OH. The event will highlight results from Galectin's NAVIGATE Phase 3 clinical trial evaluating belapectin for the treatment of MASH cirrhosis and portal. Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of MASH and fibrosis. With no approved therapies to prevent or treat varices in MASH cirrhosis, belapectin may represent the first potential treatment to address this significant unmet need. A live question and answer session will follow the formal presentations. About Naga P. Chalasani, MD Naga P. Chalasani, MD completed medical school in India before he moved to the US to pursue Internal Medicine residency at Emory University in Atlanta, followed by a fellowship in Gastroenterology and Hepatology at the same institution. He joined IU in 1997 as an Assistant Professor in the Division of Gastroenterology and Hepatology. Dr. Chalasani is currently David W. Crabb Professor of Gastroenterology and Hepatology and Adjunct Professor of Anatomy, Cell Biology & Physiology and as Director of Terance Kahn Liver Research Program at Indiana University School of Medicine. He previously served as the GI Division Chief (2007-2020), Associate Dean for Clinical Research (2017-2020) interim Chair of the Department of Medicine (2020-2021) and Vice President for Academic Affairs at Indiana University Health (2022-2024). He is a highly regarded clinician and ranked as Top Doctor continuously for over 15 years. He has been continuously funded by the National Institutes of Health (NIH) since 1999 and is currently the PI on several U01 and R01 awards from the NIH. Dr. Chalasani is considered an authority in the fields of Non-Alcoholic Fatty Liver Disease (NAFLD) and Drug Induced Liver Injury (DILI), two highly significant public health problems. He is one of the most published and most cited investigators at Indiana University, with Google Scholar H-Index 120 and 75,000 citations (as of Feb 2025). He is an elected member of the American Society of Clinical Investigation (ASCI), the American Association of Physicians (AAP) and the National Academy of Medical Sciences – India (2024). He has mentored over 75 undergraduate and graduate students, medical students, sub-specialty trainees, and junior faculty. Twenty of his mentees are recipients of federal funding (K award, U01, R21, R01, DOD, and VA Merit Review). To honor his contributions and mentorship, Naga P Chalasani Endowed Professor in Gastroenterology and Hepatology has been established at Indiana University School of Medicine in October 2022. About Naim Alkhouri, MD, FAASLD, DABOM Naim Alkhouri, MD, FAASLD, DABOM is the Chief Academic Officer at Summit Clinical Research and the Director of the Steatotic Liver Program at North Shore Gastroenterology in Cleveland, OH. Prior to joining Summit, Dr. Alkhouri served as the Chief Medical Officer and Director of the Steatotic Liver Disease program at Arizona Liver Health in Phoenix, AZ. Dr. Alkhouri is a key opinion leader in the field of MASH therapeutics and an advisor/ consultant to many pharmaceutical and biomarker development companies. He is Principal Investigator on several multicenter global MASH trials and a member of the AASLD MASLD Special Interest Group (MASLD SIG). Dr. Alkhouri has been published in over 260 publications to include publications in the New England Journal of Medicine, Lancet, JAMA, Nature Medicine, Gastroenterology, Hepatology, and Journal of Hepatology. He presents his work at both national and international medical conferences. About Galectin Therapeutics Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as 'may,' 'estimate,' 'could,' 'expect', 'look forward', 'believe', 'hope' and others. They are based on management's current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin's development program for belapectin will lead to the first therapy for the treatment of MASH, formerly known as NASH, with cirrhosis and those regarding the hope that our lead compounds will be successful in cancer immunotherapy and in other therapeutic indications. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, full analysis of the NAVIGATE trial data may not product positive data; Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of belapectin or any of its other drugs in development; the Company may not be successful in scaling up manufacturing and meeting requirements related to chemistry, manufacturing and control matters; the Company's current clinical trial and any future clinical studies may not produce positive results in a timely fashion, if at all, and could require larger and longer trials, which would be time consuming and costly; plans regarding development, approval and marketing of any of Galectin's drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies; regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. For a discussion of additional factors impacting Galectin's business, see the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements. Company Contact:Jack Callicutt, Chief Financial Officer(678) 620-3186ir@ Investor Relations Contact:Kevin Gardnerkgardner@ Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics' galectin-3 inhibitor belapectin.
Yahoo
14 minutes ago
- Yahoo
Apple Rolls Out AI-Driven iOS 26 at WWDC
Apple (NASDAQ:AAPL) kicks off its AI and design revolution with iOS 26, unveiling a Liquid Glass interface and deeper ChatGPT integrations across core apps at WWDC 2025. Apple's vice president of Human Interface Design, Alan Dye, described iOS 26 as the broadest update ever, featuring Liquid Glassa dynamic material that marries glass-like optics with fluid responsivenessapplied universally to iPhone, iPad, Watch, TV and Mac. Native apps from Camera and Safari to Messages and Wallet get fresh layouts that adapt to context, while CarPlay and Maps gain streamlined controls. On the AI front, Apple amplifies its partnership with OpenAI by embedding ChatGPT into Image Playground and Genmoji, letting users generate bespoke images and emojis from text or photoswith full user consent. Visual Intelligence now lets you ask ChatGPT about anything on your screen without switching apps, and Live Translations delivers real-time captions and translations in Messages, FaceTime and Phoneeven with non-iPhone users. Craig Federighi, SVP of Software Engineering, announced expanded Siri personalization and an open Foundation Models Framework that enables any third-party app to tap into Apple Intelligence. Why It Matters: iOS 26's Liquid Glass aesthetic and deep AI mash-up could drive device upgrade cycles and boost services revenue as Apple rolls out paid AI features. It underscores Apple's strategy to monetize AI through its hardware moat rather than by chasing model supremacy. This article first appeared on GuruFocus.
Yahoo
19 minutes ago
- Yahoo
HOTELS.COM 2025 HOTEL PRICE INDEX REVEALS THE BEST VALUE STAYS, 4-STAR SWEET SPOTS, AND WHERE PRICES ARE FALLING
New report analyzes hotel pricing trends, finding international 5-star hotels are 27% cheaper than U.S. stays with luxe options under $200 in Hanoi, Pattaya and Auckland DALLAS, June 10, 2025 /PRNewswire/ -- Today, released the 2025 Hotel Price Index™ revealing that luxury is more accessible abroad, domestic nightly rates are falling, and 4-star properties consistently offer the best value. The Hotel Price Index analyzes global year-on-year average daily rates from bookings on in the most popular international and domestic destinations and delves into pricing trends and differences between star ratings. Here are the main takeaways: Luxury Abroad = Big Savings: International 5-star hotels are, on average, 27% cheaper than their U.S. counterparts. Standout deals under $200 can be found in cities like Hanoi, Pattaya and Auckland. 4-Star Hotels Hit the Sweet Spot: U.S. travelers upgrading from 3- to 4-star hotels pay 38% more to up-star, while jumping from a 4- to 5-star property cost 118% more on average.1 Domestic Prices Dip, International Rise: U.S. hotel rates fell slightly (-2%) to $174/night, while international rates rose (+4%) to $228/night.2 VIP Access = Extra Perks: VIP Access program offers member perks that can be worth hundreds of dollars, including spa credits, free upgrades, and resort discounts at top-rated properties worldwide. Experience the full interactive Multichannel News Release here: "For price-conscious travelers in today's economy, the Hotel Price Index offers a rare, data-driven lens into where your money goes furthest. It's like a travel cheat sheet — revealing where to splurge, where to save, and where luxury quietly costs less," said Melanie Fish, Vice President of Global PR and travel expert. "Cities like Bangkok, São Paulo and Mexico City stand out for offering top-rated stays across all star levels, proving that great travel doesn't have to come with a high price tag. And for those travelers looking to stretch their dollars even further, programs like VIP Access can add unexpected value, from complimentary upgrades to spa credits, turning a good deal into a great experience." Price Insights: Where Hotel Costs Rose and Where They Didn't Some U.S. cities including San Francisco (-9%), Austin (-7%) and Atlanta (-6%) saw declines in hotel prices.3 Meanwhile, high-demand destinations like Chicago (+7%) experienced an increase. Internationally, Toronto (-3%), Amsterdam (-3%) and Istanbul (-2%) saw small decreases in average daily rates, while average prices went up year-over-year in Kyoto (+13%), Tokyo (+12%) and Madrid (+12%). Travelers looking for more affordable trending destinations that are growing in popularity should try Bogotá, Colombia (ADR of $97 a night) and Benidorm, Spain (ADR of $127 a night), offering highly rated accommodations at a fraction of the price. Five-star Luxury for Less Price insights showed that Americans looking to stretch their dollars without sacrificing luxury should consider heading abroad, where average 5-star rates are cheaper than those in the U.S. Here's where to find 5-star stays under $200: Hanoi, Vietnam: $156 a night Pattaya, Thailand: $157 a night Gothenburg, Sweden: $163 a night Panama City, Panama: $186 a night Auckland, New Zealand: $192 a night Meanwhile, these are the cheapest 5-star stays in the U.S.: Portland, Oregon: $287 a night San Antonio, Texas: $340 a night Las Vegas, Nevada: $341 a night Atlanta, Georgia: $361 a night Miami, Florida: $386 a night These are the most popular cities for U.S. travelers booking 5-star stays: Las Vegas, Nevada: $341 a night New York, New York: $639 a night London, England: $511 a night Dubai, UAE: $288 a night Bangkok, Thailand: $186 a night Star Ratings Revealed a 4-Star Suite Spot* Based on analysis, 4-star hotels offer the best value for travelers looking to up-star their domestic stays, with the average daily rate just 38% higher than at 3-star properties. Meanwhile, 5-star hotels cost, on average, 118% more than 4-star. The best value for domestic 4-star stays include: Las Vegas, Atlanta, Portland, Orlando, Denver and Houston, all of which have rates under the 4-star average of $226 a night. Though 4-stars is the sweet spot, certain destinations like Bangkok and Bogotá offer 5-star stays at near 3-star prices, redefining the meaning of affordable indulgence. Where to Score Perks Getting great value on a trip isn't just about price and star-rating; it's also about the experience. Members staying at VIP Access properties – a curated collection of top-rated hotels on – enjoy exclusive perks, discounts and earn extra rewards. In 2024, the perks travelers received most from VIP Access properties included food and beverage credits, spa credits, free beverages and bottles of wine. VIP Access perks can total more than $250 in value – more than the average cost of a night at a 4-star hotel. Here are a few hotels that offer some seriously valuable perks to members: Plan a trip by perks: From a spa credit in Puerto Vallarta to a free beverage in Sydney, travelers can peruse this new map to see which perks they can expect in popular destinations worldwide. Head to to book top-rated VIP Access hotels and other high-value stays uncovered by the Hotel Price Index here. About About The app makes it easy with almost one million places to stay around the world. So, whether you're looking for value in Vegas, treehouses in Thailand or villas with views, it's all just a search away. Now with One Key™, their comprehensive rewards program, get rewarded beyond hotels – earn and then use rewards on eligible flights, vacation rentals, and more on Expedia and Vrbo®. Members save 10% or more at select hotels when signed into the app, and Silver, Gold and Platinum members receive perks at select VIP Access™ properties, such as food and beverage discounts. © 2025 LP, an Expedia Group company. All rights reserved. and the logo are trademarks of LP. CST# 2083949-50 For more information use our mobile app or visit Follow on Instagram, TikTok, Facebook and X. 1 Compares average daily rates of 3, 4, and 5-star hotels from 1/01/2024 -12/31/20242 Compares year over year average daily rates from 1/1/2024 to 12/31/2024 compared to 1/1/ 2023 to 12/31/20233 Compares year over year average daily rates from 1/1/2024 to 12/31/2024 compared to 1/1/ 2023 to 12/31/2023 View original content: SOURCE Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
